Literature DB >> 7688770

The autoimmune blistering skin disease bullous pemphigoid. The presence of plasmin/alpha 2-antiplasmin complexes in skin blister fluid indicates plasmin generation in lesional skin.

M D Kramer1, J Reinartz.   

Abstract

Plasminogen activators produced locally in the skin have been implicated in blistering skin diseases. To explore whether plasminogen activators convert their substrate plasminogen into plasmin locally in the lesional skin we have analyzed the autoimmune blistering skin disease bullous pemphigoid. Enzyme activity was detected in bullous pemphigoid skin blister fluid by using a low molecular weight chromogenic substrate for plasmin. Enzyme activity was detected neither in suction blister fluid raised on normal skin nor in normal plasma. Immunoprecipitation or fractionation by molecular sieve chromatography of bullous pemphigoid skin blister fluid followed by testing in immunoassays disclosed putative plasmin/alpha 2-macroglobulin complexes and plasmin/alpha 2-antiplasmin complexes. Enzyme activity detected in bullous pemphigoid skin blister fluid by the low molecular weight chromogenic peptide assay was ascribed to the putative plasmin pha 2-macroglobulin complexes. Because formation of plasmin-inhibitor complexes requires the active plasmin, our findings indicate previous activation of plasminogen to plasmin in skin lesions. There was no evidence for free plasmin (i.e., plasmin not complexed to inhibitors) in bullous pemphigoid blister fluid, suction blister fluid, or plasma.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7688770      PMCID: PMC294938          DOI: 10.1172/JCI116674

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  26 in total

Review 1.  Plasminogen activators, tissue degradation, and cancer.

Authors:  K Danø; P A Andreasen; J Grøndahl-Hansen; P Kristensen; L S Nielsen; L Skriver
Journal:  Adv Cancer Res       Date:  1985       Impact factor: 6.242

2.  Subepidermal bullous diseases.

Authors:  E R Farmer
Journal:  J Cutan Pathol       Date:  1985 Jun-Aug       Impact factor: 1.587

Review 3.  Human plasma proteinase inhibitors.

Authors:  J Travis; G S Salvesen
Journal:  Annu Rev Biochem       Date:  1983       Impact factor: 23.643

4.  Chromogenic peptide substrates. Their use for the assay of factors in the fibrinolytic and the plasma kallikrein-kinin systems.

Authors:  P Friberger
Journal:  Scand J Clin Lab Invest Suppl       Date:  1982

5.  Acid hydrolases in blister fluid. 3. Characterization and quantification of peptide hydrolases.

Authors:  G Volden
Journal:  Br J Dermatol       Date:  1978-07       Impact factor: 9.302

Review 6.  On the regulation and control of fibrinolysis. Edward Kowalski Memorial Lecture.

Authors:  D Collen
Journal:  Thromb Haemost       Date:  1980-06-18       Impact factor: 5.249

7.  Proteinase activation: a mechanism for cellular dyshesion in pemphigus.

Authors:  K H Singer; N J Sawka; H R Samowitz; G S Lazarus
Journal:  J Invest Dermatol       Date:  1980-05       Impact factor: 8.551

8.  Enhanced association of plasminogen/plasmin with lesional epidermis of bullous pemphigoid.

Authors:  H M Gissler; M M Simon; M D Kramer
Journal:  Br J Dermatol       Date:  1992-09       Impact factor: 9.302

9.  Plasminogen is present in the basal layer of the epidermis.

Authors:  R R Isseroff; D B Rifkin
Journal:  J Invest Dermatol       Date:  1983-04       Impact factor: 8.551

10.  Synthesis of human plasminogen by the liver.

Authors:  D Raum; D Marcus; C A Alper; R Levey; P D Taylor; T E Starzl
Journal:  Science       Date:  1980-05-30       Impact factor: 47.728

View more
  12 in total

1.  A critical role for neutrophil elastase in experimental bullous pemphigoid.

Authors:  Z Liu; S D Shapiro; X Zhou; S S Twining; R M Senior; G J Giudice; J A Fairley; L A Diaz
Journal:  J Clin Invest       Date:  2000-01       Impact factor: 14.808

2.  alpha 2-Antiplasmin and plasminogen activator inhibitors in healing human skin wounds.

Authors:  B M Schaefer; K Maier; U Eickhoff; M Bechtel; M D Kramer
Journal:  Arch Dermatol Res       Date:  1996-03       Impact factor: 3.017

3.  Synergy between a plasminogen cascade and MMP-9 in autoimmune disease.

Authors:  Zhi Liu; Ning Li; Luis A Diaz; Michael Shipley; Robert M Senior; Zena Werb
Journal:  J Clin Invest       Date:  2005-04       Impact factor: 14.808

4.  Neutrophil elastase cleaves the murine hemidesmosomal protein BP180/type XVII collagen and generates degradation products that modulate experimental bullous pemphigoid.

Authors:  Lan Lin; Tomoko Betsuyaku; Lisa Heimbach; Ning Li; David Rubenstein; Steven D Shapiro; Lijia An; George J Giudice; Luis A Diaz; Robert M Senior; Zhi Liu
Journal:  Matrix Biol       Date:  2011-09-25       Impact factor: 11.583

5.  Subepidermal blistering induced by human autoantibodies to BP180 requires innate immune players in a humanized bullous pemphigoid mouse model.

Authors:  Zhi Liu; Wen Sui; Minglang Zhao; Zhuowei Li; Ning Li; Randy Thresher; George J Giudice; Janet A Fairley; Cassian Sitaru; Detlef Zillikens; Gang Ning; M Peter Marinkovich; Luis A Diaz
Journal:  J Autoimmun       Date:  2008-10-14       Impact factor: 7.094

6.  Elevated expression and release of tissue-type, but not urokinase-type, plasminogen activator after binding of autoantibodies to bullous pemphigoid antigen 180 in cultured human keratinocytes.

Authors:  E Schmidt; B Wehr; E M Tabengwa; S Reimer; E-B Bröcker; D Zillikens
Journal:  Clin Exp Immunol       Date:  2004-03       Impact factor: 4.330

Review 7.  The pathophysiology of bullous pemphigoid.

Authors:  Michael Kasperkiewicz; Detlef Zillikens
Journal:  Clin Rev Allergy Immunol       Date:  2007-10       Impact factor: 8.667

8.  Prothrombotic state and impaired fibrinolysis in bullous pemphigoid, the most frequent autoimmune blistering disease.

Authors:  A V Marzano; A Tedeschi; I Polloni; C Crosti; M Cugno
Journal:  Clin Exp Immunol       Date:  2013-01       Impact factor: 4.330

9.  Gelatinase B-deficient mice are resistant to experimental bullous pemphigoid.

Authors:  Z Liu; J M Shipley; T H Vu; X Zhou; L A Diaz; Z Werb; R M Senior
Journal:  J Exp Med       Date:  1998-08-03       Impact factor: 14.307

Review 10.  Experimental models for the autoimmune and inflammatory blistering disease, Bullous pemphigoid.

Authors:  Lisa Leighty; Ning Li; Luis A Diaz; Zhi Liu
Journal:  Arch Dermatol Res       Date:  2007-09-19       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.